Abstract: The invention is directed to a method for diagnosing and treating a pulmonary lung disease by detecting a mutant S100A3 protein associated with pulmonary lung disease and by treating a subject with a functional S100A3 protein.
Type:
Grant
Filed:
October 26, 2020
Date of Patent:
May 28, 2024
Assignee:
KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE
Inventors:
Eid Abdullah Al Mutairy, Mohammed Khalid, Futwan Al-Mohanna
Abstract: This patent relates to a method of treating IgG4-related disease comprising administration of an Interleukin-4 inhibitor/antagonist, an IL-4 receptor alpha inhibitor, or a compound which blocks assembly of IL-4 receptor alpha with IL-13 receptor alpha. The method of treating IgG4-related disease may comprise administration of a JAK inhibitor. The method of treating IgG4-related disease may comprise administration of duplimab and/or pitrakinra.
Abstract: Herein is reported a method for the purification of a protein comprising erythropoietin and a single poly (ethylene glycol) residue from reaction by-products or not reacted starting material by a cation exchange chromatography method. It has been found that by employing a cation exchange Toyopearl® SP-650 chromatography material and employing a second wash step with an increased pH value compared to the first wash step a fusion protein of erythropoietin and a single poly (ethylene glycol) residue can be obtained in a single step with high purity and yield and suitability for large scale applications.
Type:
Grant
Filed:
January 11, 2021
Date of Patent:
May 28, 2024
Assignee:
HOFFMANN-LA ROCHE INC
Inventors:
Roberto Falkenstein, Bernhard Spensberger
Abstract: Using expression of CC chemokine ligand (CCL24) to serve as an identification of a potential deriver of metastatic cancers and methods of detecting the presence of CCL24 to serve as a breast cancer diagnosis tool.
Abstract: The present disclosure relates to a dual-function protein for regulating blood glucose and lipid metabolism, wherein said dual-function protein comprises a human GLP-1 analog and human FGF21. In the present disclosure, provided is a method for preparing said dual function protein, and also provided is the use of said dual-function protein in the preparation of a biological substance for treating type 2 diabetes, obesity, dyslipidemia, fatty liver disease and/or metabolic syndrome. The dual-function protein provided in the present disclosure can synergistically regulate blood glucose and lipid levels in vivo, and satisfy multiple requirements for patients with type 2 diabetes such as lowering blood glucose, relieving hepatic steatosis, reducing body weight and improving metabolic disorders of circulating lipids.
Type:
Grant
Filed:
May 27, 2020
Date of Patent:
May 14, 2024
Assignee:
AMPSOURCE BIOPHARMA SHANGHAI INC.
Inventors:
Zhao Dong, Chi Zhou, Xiong Feng, Jiyu Zhang, Shixiang Jia, Qiang Li
Abstract: Mutant M-CSF protein, comprising ?v?3 integrin binding motif and pharmaceutical compositions comprising same, are provided. Further, use of the composition for the treatment and or prevention of diseases associated with increased bone resorption are provided.
Type:
Grant
Filed:
August 4, 2021
Date of Patent:
May 7, 2024
Assignees:
THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD., B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY
Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy.
Abstract: The present invention provides compositions and method for treating a subject having or suspected of having pulmonary dysfunction resulting from impaired alveolar macrophage (AM) development. The compositions comprise granulocyte-macrophage colony stimulating factor (GM-CSF) in formulations suitable for pulmonary airway administration.
Type:
Grant
Filed:
April 9, 2020
Date of Patent:
April 23, 2024
Assignee:
Washington University
Inventors:
Sharon Celeste Morley, Elizabeth M. Todd
Abstract: Described herein are compositions and kits that comprise an engineered TL1A ligand that displays high stability, minimal binding to decoy receptor DcR3 while retaining functional activity via binding to its cell surface receptor, DR3, and the ability to activate T cells in vitro and in vivo. Methods of making an engineered TL1A ligand and methods of treating a disease or disorder in a subject by administering an engineered TL1A ligand are also provided.
Type:
Grant
Filed:
August 18, 2021
Date of Patent:
April 9, 2024
Assignee:
Janssen Biotech, Inc.
Inventors:
Adam Zwolak, Szeman Chan, Rajkumar Ganesan
Abstract: The present invention provides novel biomaterial compositions and methods having a technology to improve retention of hyaluronic acid (HA). The biomaterial compositions utilize small HA binding peptides and extracellular matrix binding (ECM) peptides that are tethered to synthetic biocompatible polymers. When tethered to the polymers, the peptide region allows the polymers to bind to HA and to tissues such as cartilage. The novel biomaterial compositions can be used to coat or chemically modify cartilage or tissues with a biologically compatible polymer having HA binding peptides, which allow HA to bind to the surface of the cartilage or tissues. Methods of using same are also provided.
Type:
Grant
Filed:
August 27, 2021
Date of Patent:
April 2, 2024
Assignee:
THE JOHNS HOPKINS UNIVERSITY
Inventors:
Anirudha Singh, Shimon Unterman, Michael Corvelli, Jennifer Elisseeff
Abstract: The present invention provides monoclonal antibodies that bind to the Activin A type I receptor (ACVR1) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to ACVR1. In some embodiments, the antibodies of the invention are useful for inhibiting ACVR1-mediated bone morphogenetic protein (BMP) signal transduction, thus providing a means of treating or preventing a disease, disorder or condition associated with ACVR1.
Type:
Grant
Filed:
February 10, 2021
Date of Patent:
April 2, 2024
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Vincent J. Idone, Sarah J. Hatsell, Aris N. Economides
Abstract: The present invention relates to methods of treating subjects suffering from a pulmonary NTM infection refractory to treatment, for example to antibiotic treatment.
Type:
Grant
Filed:
October 16, 2018
Date of Patent:
March 26, 2024
Assignees:
drugrecure APS, Mayo Foundation for Medical Education and Research
Inventors:
Inge Tarnow, Cecilia Ganslandt, Mark E. Wylam
Abstract: Novel compositions that promote hair growth or hair restoration, and compositions that prevent hair loss. Compositions including an iNOS inhibitor as an active ingredient are provided. Advantageous affects for hair growth or hair restoration are obtained when a composition including an iNOS inhibitor as an active ingredient is administered to a mammal. For the iNOS inhibitor, a low-molecular compound, an antibody, or a nucleic acid drug such as an antisense oligonucleotide or siRNA may be used. A method of screening for effective substances for promotion of hair growth or hair restoration or prevention of hair loss is also provided.
Abstract: The present application provides methods and processes for making and using a fibronectin composition, as well as methods for treating ocular conditions and/or disorders with the cellular fibronectin composition described herein.
Abstract: Fusion proteins comprising an extracellular domain of PD1 (programmed cell death protein-1) protein and/or an extracellular domain of PD-L1 (programmed cell death-ligand 1 protein (CD274 or B7-H1)) protein. Portions of the extracellular domains are expressed in specific configurations and purified as protein and used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. Also described is a method of determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient, wherein a patient has undergone at least one dose of immunotherapy.
Type:
Grant
Filed:
November 29, 2018
Date of Patent:
March 5, 2024
Assignee:
GRIFOLS DIAGNOSTIC SOLUTIONS INC.
Inventors:
Jody Berry, Elizabeth Antony Booth, Joyee Antony George, Elisabete Nascimento, Daniel Nagore Casas
Abstract: This invention discloses a bifunctional TGF-B/immune checkpoint fusion gene and protein with anti-inflammatory activity that represents a new class of therapy for Immune disorders, immune dysregulation, and autoimmune diseases. The bifunctional TGF-B/immune checkpoint fusion gene and protein include: (i) a TGF-B domain consists of TGF-B1 (ii) an immune checkpoint consisting of PD-L1, (iii) a flexible peptide linker that links two TGF-B domains resulting in a dimeric TGF-B construct wherein the dimeric form of the TGF-B ligand is important for its binding and functional activity, and (iv) a rigid peptide linker, wherein the dimeric TGF-B ligand is linked to the immune checkpoint ligand. A unique feature of this invention is the engineering of a dimeric TGF-B1 domain in the TGF-B1/PD-L1 fusion protein which was experimentally shown to be important in its binding to its TFGBR1 receptor and its functional activity.
Abstract: The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.
Abstract: The present invention provides methods of making an in vivo animal model for detecting anti-poly(ethylene glycol) (PEG) antibodies. The methods of the disclosure comprises administering subcutaneously to an animal model a composition comprising antibodies against poly(ethylene glycol) chains with a molecular weight of at least 550 Da to maintain an anti-PEG antibody level within the animal model. The in vivo animal model can be used for testing and screening drugs and other compositions for adverse reactions, bioavailability, and immunogenicity prior to administration to a human subject.
Type:
Grant
Filed:
October 15, 2020
Date of Patent:
February 6, 2024
Assignee:
Northwestern University
Inventors:
Evan A. Scott, Guillermo A. Ameer, Jacqueline A. Burke, Helena Freire Haddad
Abstract: The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.
Abstract: The present application provides methods and processes for making and using a fibronectin composition, as well as methods for treating ocular conditions and/or disorders with the cellular fibronectin composition described herein.